Royalty Report: Medical, Device, Delivery – Collection: 369267


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Medical
  • Device
  • Delivery
  • Drugs
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369267

License Grant
For the Research License, Licensor grants a non-exclusive license, without any right to grant sublicenses, under the Licensor IP solely to the extent necessary for Licensee to perform activities allocated to Licensee under the Workplans.

For the Commercialization License, Licensor grants an exclusive license, with the right to grant sublicenses, under the Licensor IP to Research, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Licensed Products in the Field in the Territory, provided that Licensor shall retain the exclusive right to manufacture and supply to Licensee the Microinjector component of Licensed Products.

License Property
Licensor is a biopharmaceutical company with proprietary technology designed to administer drugs to the targeted tissue of the eye using a microneedle injection into the suprachoroidal space and related formulation technology

Gene Therapeutic means any product incorporating a Vector and a nucleic acid that confers a therapeutic benefit.

Licensed Product means any product that incorporates a Gene Therapeutic delivered with the use of a Microinjector.

Microinjector means any device containing a microneedle for injecting material into the suprachoroidal space that comprises Licensor Technology.

The patents include Apparatus and Formulations for Suprachoroidal Drug Delivery, and, Device for Ocular Access.

Field of Use
SCS Microinjector technology and related intellectual property are used in delivering gene therapies to the back of the eye.  Using a proprietary microinjector, the technology delivers therapeutic agents to the retina and choroid through the SCS and without substantial diffusion to the vitreous of the eye.

SCS injection platform, utilizing the proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

The Field means delivery of any ocular Gene Therapeutic for all ophthalmic therapeutic, diagnostic, prophylactic, palliative and veterinary purposes.

IPSCIO Record ID: 297723

License Grant
Pursuant to the License Agreement, the Licensor has granted an exclusive license to the Hong Kong Licensee to develop, distribute, promote, market and commercialize XIPERE, subject to specified exceptions in the Territory.
License Property
XIPERE, is proprietary suspension of the corticosteroid triamcinolone acetonide.  The formulated product is for administration to the back of the eye, using the Licensor’s proprietary SCS Microinjector, the device.
Field of Use
The patented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye.

The field of use is for the treatment of macular edema associated with uveitis.

Uveitis is a form of eye inflammation. It affects the middle layer of tissue in the eye wall (uvea). Uveitis (u-vee-I-tis) warning signs often come on suddenly and get worse quickly. They include eye redness, pain and blurred vision. The condition can affect one or both eye. Macular edema is the build-up of fluid in the macula, an area in the center of the retina.

IPSCIO Record ID: 344589

License Grant
Licensor grants an exclusive, worldwide license and sublicense, with the right to sublicense, under the Licensor Technology, based on existing agreements in place, to research, develop, use, have used, make, have made, import or have imported, export or have exported, offer for sale or have offered for sale, and/or sell or have sold Licensed Products in the Field.
License Property
The various patents relate to Treating Ocular Disorders and include but are not limited to
Susceptibility Genes for Age Related Maculopathy (ARM) on Chromosome 10q26;
Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration;
Methods for Diagnosing, Preventing or Treating Drusen Formation;
Diagnostics and Therapeutics for Aortic Aneurysm;
Diagnostics and Therapeutics for Ocular disorders;
Diagnostics and Therapeutics for Drusen Associated Ocular Disorders;
Diagnostics and therapeutics for macular degeneration-related disorders;
Factor H-Based Diagnostics;
Methods and Compositions for Treating Ocular Disorders;
Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration;
Association of SNPs with Complement Related Diseases;
Genetic Variants Increase the Risk of Age-Related Macular Degeneration;
Diagnosis and Therapeutic Target for Macular Degeneration;
Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration;
Method Evolved · for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd);
Method of Detecting Ocular Diseases and Pathologic Conditions and Treatment of Same; and,
Genes Associated with Macular Degeneration.
Field of Use
Licensee has the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

AMD is an insidious progressive eye disorder that starts with relatively harmless tiny yellow deposits on the retina (the light sensitive tissue in the eye) and increases in prevalence and severity with age. The end stage of this condition, called neovascular or 'wet AMD', develops in 10 to 20% of all cases, causes profound loss of central vision and is the leading source of legal blindness in people over age 50 in the developed world. It is caused by abnormal growth of fragile and leaky blood vessels (choroidal neovascularization or 'CNV') in the macula (a small area where vision is keenest at the center of the retina) in response to chronic inflammatory stress.

Field shall mean any and all diagnostic, which includes prognostic, uses for research, laboratory developed tests or in vitro diagnostic tests markets, for use with any and all types of technology platforms.

IPSCIO Record ID: 299233

License Grant
University grants the exclusive worldwide right and license to make, have made, use, import, export, lease and sell the Licensed Products, and to practice the Licensed Processes to the end of the term for which the Patent Rights are granted unless sooner terminated according to the terms hereof.
License Property
The University has patents for Intraretinal Delivery System.  The license relates to a patented device for the controlled, non-surgical delivery of ophthalmic drugs to the retina and other tissues in the posterior chamber of the eye.
Field of Use
Licensee develops genetically-based tools for the diagnosis and prognosis of glaucoma, ophthalmic, and pharmaceutical products based on its proprietary eyedrop-based drug delivery technology, and, the Company licensed a device for the delivery of drugs to the retina.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.